Literature DB >> 10697118

Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus.

T Schnell1, P Foley, M Wirth, J Münch, K Uberla.   

Abstract

In contrast to oncoviruses, lentiviruses do not require target cell division for integration into the host genome. Lentiviral vectors can therefore expand the spectrum of target cells susceptible to retroviral gene transfer. To analyze whether vectors based on simian immunodeficiency viruses (SIVs) could be used for gene transfer, a three-plasmid vector-packaging system was developed, in which Gag-Pol and the vector itself are of SIV origin, while Env is derived either from SIV, amphotropic murine leukemia virus (MuLV), or the G glycoprotein of vesicular stomatitis virus (VSV-G). To increase the safety of the SIV vector system, a self-inactivating SIV vector was constructed. After optimization of the SIV gag-pol expression plasmid, a minimal SIV vector, which contained only SIV sequences present on the multiply spliced nef transcript, could still be produced at titers of 2 x 10(5) infectious units/ml. Growth-arrested cells could be transduced with this vector even if vif, vpr, vpx, and nef had been deleted from the packaging construct and the vector.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10697118     DOI: 10.1089/10430340050015905

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  34 in total

1.  Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells.

Authors:  P E Mangeot; D Nègre; B Dubois; A J Winter; P Leissner; M Mehtali; D Kaiserlian; F L Cosset; J L Darlix
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems.

Authors:  Elena Grabski; Zoe Waibler; Silke Schüle; Björn-Philipp Kloke; Linda Y Sender; Sylvia Panitz; Klaus Cichutek; Matthias Schweizer; Ulrich Kalinke
Journal:  Mol Biotechnol       Date:  2011-03       Impact factor: 2.695

3.  Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors.

Authors:  Hideki Hanawa; Derek A Persons; Arthur W Nienhuis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

5.  Viral determinants of integration site preferences of simian immunodeficiency virus-based vectors.

Authors:  Hella Monse; Stephanie Laufs; Seraphin Kuate; W Jens Zeller; Stefan Fruehauf; Klaus Uberla
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

7.  Transgene expression in the mouse cerebellar Purkinje cells with a minimal level of integration using long terminal repeat-modified lentiviral vectors.

Authors:  Kiyohiko Takayama; Takashi Torashima
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

8.  Reduced mobilization of Rev-responsive element-deficient lentiviral vectors.

Authors:  Susann Lucke; Thomas Grunwald; Klaus Uberla
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 9.  Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.

Authors:  Chang Liu; Li Zhang; Hao Liu; Kun Cheng
Journal:  J Control Release       Date:  2017-09-11       Impact factor: 9.776

10.  Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Authors:  Barbara Falkensammer; Barbara Rubner; Alexander Hiltgartner; Doris Wilflingseder; Christiane Stahl Hennig; Seraphin Kuate; Klaus Uberla; Stephen Norley; Alexander Strasak; Paul Racz; Heribert Stoiber
Journal:  Retrovirology       Date:  2009-06-21       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.